James Investment Research Inc Incyte Corp Transaction History

James Investment Research Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 27, 2021	SELL	$80.74 - $97.7 $80,740 - $97,700	-1,000 Closed	0 $0
Q3 2020 Oct 23, 2020	SELL	$85.07 - $109.69 $252,657 - $325,779	-2,970 Reduced 74.81%	1,000 $90,000
Q2 2020 Jul 24, 2020	SELL	$74.18 - $108.93 $13,352 - $19,607	-180 Reduced 4.34%	3,970 $0
Q1 2020 Apr 22, 2020	SELL	$63.18 - $85.97 $1.42 Million - $1.93 Million	-22,423 Reduced 84.38%	4,150 $0
Q4 2019 Jan 24, 2020	BUY	$73.04 - $95.72 $214,153 - $280,651	2,932 Added 12.4%	26,573 $2.32 Million
Q3 2019 Oct 30, 2019	BUY	$72.82 - $86.52 $1.72 Million - $2.05 Million	23,641 New	23,641 $0

640

187M

729K

479K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $17.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of James Investment Research Inc, based on Form 13F filings with the SEC.

Stay updated on James Investment Research Inc with notifications on news.